Premium
Randomized controlled trial of adenine arabinoside 5′‐monophosphate in chronic active hepatitis B: Comparison of the efficacy in heterosexual and homosexual patients
Author(s) -
Marcellin Patrick,
Ouzan Denis,
Degos Françoise,
Brechot Christian,
Metman EtienneHenri,
Degott Claude,
Chevalier Michelle,
Berthelot Pierre,
Trepo Christian,
Benhamou JeanPierre
Publication year - 1989
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840100313
Subject(s) - randomized controlled trial , medicine , chronic hepatitis , virology , gastroenterology , virus
Twenty‐two heterosexuals and 21 homosexuals with chronic active hepatitis B and who had HBsAg, HBeAg and hepatitis B virus DNA in serum were randomized separately to receive adenine arabinoside monophos‐phate or placebo. In the 10 heterosexuals and nine homosexuals who received placebo, no change in hepatitis B virus DNA level and HBeAg was observed. Among the patients who received adenine arabinoside mono‐phosphate, seven of the 12 heterosexuals and five of the 12 homosexuals lost hepatitis B virus DNA; five heterosexuals and three homosexuals also lost HBeAg; one homosexual lost HBsAg. There was no significant difference in response between heterosexual and homosexual patients. When results were pooled, there was a significant effect of adenine arabinoside monophosphate on hepatitis B virus replication. None of the 19 patients who received placebo but 50% of the 24 patients who received adenine arabinoside monophosphate were negative for serum hepatitis B virus DNA at 10 months after treatment (p < 0.001) and none of the 19 patients who received placebo and 33% of the 24 patients who received adenine arabinoside monophosphate were negative for HBeAg in serum (p < 0.005). Retrospective analysis showed that disappearance of hepatitis B virus DNA after administration of adenine arabinoside monophosphate was more common (i) in patients with a low pretreatment hepatitis B virus DNA level than in patients with a high pretreatment hepatitis B virus DNA level (8/11 vs. 4/13, p < 0.05); (ii) in patients with a high pretreatment ALT level than in patients with a low pretreatment ALT level (10/14 vs. 2/10, p < 0.05). Thus, homosexuals with chronic hepatitis B respond just as frequently as heterosexuals to adenine arabinoside monophosphate treatment, and the degree of hepatitis B virus replication, as reflected by serum HBV DNA level, and the degree of activity, as reflected by serum ALT level, are significant factors for predicting response to treatment.